by Andreu Prados
Probiotics are commonly used in clinical practice for digestive ailments. Some clinical trials also support the use of specific probiotics, taken orally or vaginally, for restoring the vaginal microbiota and managing bacterial vaginosis and vulvovaginal candidiasis. Here’s what we know.
by Andreu Prados, Patrice D. Cani
Studies over the last decade have brought new hope that gut microbiome-targeted therapeutics might offer novel treatments for obesity. In this post, we ask whether dietary interventions, prebiotics, probiotics and medication that target the microbiome are useful for weight management.
by Andreu Prados, Joël Doré
The 11th Gut Microbiota for Health World Summit focused on emerging gut microbiome-targeted treatments in digestive, immune and cardiometabolic health. This post highlights the major take-aways from the conference and explores how they might impact clinical practice in the foreseeable future.
by Konstantina Zafeiropoulou
Following the GMFH 2022 Year at a Glance report, it is time for a flashback in the latest research on cancer microbiome. This post ranges between the epidemiology, etiology and diagnosis of cancer, looking at the role of fungal and bacterial gut microbiome in all three health care branches.
by GMFH Editing Team
Significant strides have been made in our comprehension of the role of the gut microbiome in health and disease throughout the year 2022. We invite you to take a closer look at the "2022 Year at a Glance" report and learn about the groundbreaking discoveries made.
by GMFH Editing Team
The Human Microbiome Action project is inviting experts in microbiome-based biomarker development to participate in a Delphi survey.
by Andreu Prados
While fecal microbiota transplants are recommended for multiple recurrent Clostridioides difficile infection, their use in clinical practice is hindered by a lack of regulation and understanding of the underlying ecological dynamics. This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives (Part 6).
by GMFH Editing Team
It has been 10 years since GMFH was launched with the aim of disseminating the latest gut microbiome research to the lay public, healthcare professionals and scientists alike. In this article, members of the GMFH board of experts share their pick of the most significant advances in the field, outlining their clinical impact and implications for further research.
by Andreu Prados
A wide range of diseases, from irritable bowel syndrome to depression, have been associated with increased intestinal permeability or ‘leaky gut’. What does a leaky gut mean, how can it be diagnosed and what available dietary strategies work for managing it?
by Andreu Prados
Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).
